
    
      PX-866 is a targeted inhibitor of PI-3K. This study is being conducted to determine the
      maximally tolerated dose of PX-866 when given orally on two different schedules: daily on
      days 1-5 and 8-12 of a 28 day cycle and daily on days 1-28 of a 28 day cycle.
    
  